Drugs / pEYS606
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03308045 | Apr 2017 → Jun 2021 | uveitis | Eyevensys | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pEYS606 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03308045 ↗ |
| Action | Inhibit | “encoding a fusion protein consisting of the extracellular domain of the soluble p55 TNF-α receptor linked to the human IgG1 Fc domain (hTNFR-Is/hIgG1 or Protein 6), with high...” PMID 30009894 ↗ Aug 2018 |
| Modality | Other / unclassified | “non-viral gene therapy using plasmid electrotransfer in the ciliary muscle has been proposed” PMID 30009894 ↗ Aug 2018 |
| Route | Other | “administered by electrotransfection into the ciliary muscle” NCT03308045 ↗ |
| Target | TNF | “encoding a fusion protein consisting of the extracellular domain of the soluble p55 TNF-α receptor linked to the human IgG1 Fc domain (hTNFR-Is/hIgG1 or Protein 6), with high...” PMID 30009894 ↗ Aug 2018 |